3T Biosciences Appoints Industry Veteran John Connolly as Interim CEO
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 /PRNewswire/ 3T Biosciences, an immunotherapy company, today announced that John Connolly, Ph.D. has been appointed as interim CEO. Together with the current leadership team, Dr. Connolly will lead the next round of financing with an emphasis on leveraging the company s 3T-TRACE™ technology for novel target discovery and therapeutic development.
John Connolly, Interim CEO, 3T Biosciences John has vast experience building and leading research and clinical programs in cell and gene therapy. It s an honor to have him guiding our program as we advance this business to the next phase of its evolution. Given his past and current experience, John has a successful track record of helping to raise capital and collaborating with innovative biopharmaceutical companies across the globe, stated Hanspeter Gerber, Ph.D.,
Why India s doctors differ on Covid-19 plasma therapy
By Vikas Pandey
image captionRecovered patients from all over the world have come forward to donate plasma
Desperate calls for blood plasma to treat Covid-19 patients continue to appear on India s social media platforms even as doctors have mixed views about the experimental therapy.
When people have Covid-19 or other viral diseases, their immune system responds by creating antibodies, which attack the virus. Over time the antibodies build up and can be found in plasma - the liquid portion of the blood.
India s health authorities, like many around the world, have allowed the use of plasma to treat severely ill patients as Covid-19 continues to claim lives. The therapy also requires the consent of patients and their families.